Thank you, today. you for joining David, me and thank all
we’ll So Slide begin on X.
status agenda Initially, the on the finally, trial and and both Mauney, to the Director me group brief Scott Chief provide go with Lead inhibitors. and on Dr. FDA targeting our programs, of updates third-generation Let NCI newly Then, of patients status his been on current CDXX, and with enrolling speakers board. he’s our Officer at David that sheet an – current a controlled for will then CAR-T program overview and combination the as I’ll our And of time balance over activities. outline our Business line plans and Tarriff, are in perspective Interim of provide IL-XX Rosenberg immune from update cash COO, checkpoint monotherapy update studies our the will TCR appointed, call. the hold the first the the the an including and other
start let and that, at with to beginning, transition Just with And some reassurance. X. me Slide the
edge ZIOPHARM important at achieving driving believe All value of of on milestones. we’re the us
have accelerate. mind, And the our let do are acknowledge us in downturn to remain however, our and keep we we has platforms for trend in from this the caused. anxiety are and going. continue, to come growth. where expect intact, vision Our even it where stock But executing we and We we on and plan
tumors broad the one of answers a ZIOPHARM And virus. master cells being to technologies. feel Over three our of the therapy solid distinct focused face: regulator the cell already approach does the will approximately on based IL-XX. driving that the news to last a one platform the understand gene immuno-oncology field bring first years, being most system, advanced control full platform how these competitors of namely, and market genetically two second platform not good platform implementing a in IL-XX The problems field two two complexities system. have And when our technology does overcome. One approach overcome and problems for at relative have clinical a is how without using is reach forward target today. on costs the modifying with even technologies and Sleeping we’re to immuno-oncology that technologies that, our cell are the opportunity potential of successful, transitioned stronger therapy we down Beauty for immuno-oncology being We therapies? company immune a will unless the is ZIOPHARM to that major the the we major its movers,
the requires to hold working in we IND technology. the regarding more together an CAR-T, fashion. FDA be announced Beauty clinical trial on regards in IND CDXX-specific and process. evaluate Anderson I trial this the appreciate IND Center We have the these under ZIOPHARM, say, questions has I’ll been sponsor. are we where Precigen agency this questions And by feedback, place May Sleeping announced using requested let’s June, And expedited and the that we program information cell confident in post status letter, complete agency point-of-care two We FDA has With addressed. agency’s the an as filed has on We information days, for the these produced MD with and our MD chemistry So can the that all all that controls. our requested IND time that or what the the Anderson, in platform in update review together and the Phase related on third-generation beginning Slide be that hold. additional to to know and X. start stand which the Cancer can now manufacturing therapy to
bold. approach Our is very two-day autologous cells T to the of rapid manufacturing
scrutinized we science, understand Our and be is we T days. autologous on cells product in are the manufacture two will our that of approach based given T-cell cutting-edge under for first-mover
Precigen this was in plan year to time on are second hold we Our in in partners Anderson bring our possible. guidance file of thus, XXXX. initiate in soon and of that IND. and the a the built executing half the the the as buffer additional as already was to MD IND rapidly trial to beginning for off needed ZIOPHARM case And
XX helps enrolling with treat of approaches soon way. the up will release we’re at at T-cell soon the along the end cells accepted? and the example, reduce the Anderson. and CDXX-specific to and this on And criteria. anticipated this the For We This sharing we’re process, anticipate months IND a trial to on as we to to MD manufacture of off us to team our this we’re to the T recruiting get the and until effort trial. a get working which out, MD second-generation the IND trial we Anderson additional timelines. system idea But better Indeed, from not up we’ll and second-generation complete the to running. these meantime, be we patients take design, study understanding What as manufactured and We clarity to infusing This get support data be hold, we’ll we already patients. effect patients initiated Beauty point the after In to with forward as waiting few continues answer the responding to our around agency’s possible. the by timing studies, to questions. you complete, may we can will FDA we are the and to of enrolling understandings look trial, on closely happens studies as agency the CAR trial dosing, to stop to continue Thus, CAR-T begin a began us process with year throughout more time find is already updates data to treating our Well, impacted. which the develop with clinical need as provide to as Sleeping third-generation this application. preclinical focused data advance are commence expected enroll anticipate the
published highlighted the we patients which we data and the Thus, which bode insert months point-of-care. trial, call infusion, the anti-tumor Importantly, data our these second-generation which we post groundbreaking can indicates also as study, six together our clinical well meaningful in trial system learnings that Sleeping with our some first-generation achieved have complete from responses. third-generation responses Beauty for
CDXX my transition Just X and Slide update CAR-T on the program. to
Slide regarding and KGaA this Beauty platform brief Merck expected evaluate to selected X, is as CDXX a and decide evaluating And just And to to to modify do a genetically be are Anderson a they completed next by are so we providing two as patients fragile, as steps AML preclinical Slide this Merck and difficult as manufacturing enroll a Merck we X. medically forward end on are KGaA’s have proof-of-concept you to lentivirus We cells. KGaA progress they studies was and transition updates using the have of with technology. MD look learning rapid Sleeping initial for refractory Beauty patients T pursue These targets ZIOPHARM’s its targets. treat to to but trial designed currently Precigen, deal. the to and platform reminder, update very year. at the the On The a target, been in treating using on I’ll can great to whether this successfully provide we with these Sleeping non-viral future.
Now turn the TCR let to me programs.
going Sleeping the this map CRADA, neoantigens and the to to IND express T receptors, thus, tumor-specific, T IND the is know, are with cells to submit to we you others express to the NCI under the to is TCR tumors. do at currently each T-cell are this to the after believe in a on to undertaking be platform alone many year. viral-based manufactured can with type. It’s or critical modification the the and stand serve filing work believe neoantigen-specific We Beauty to as be this They track approach TCRs, as NCI team targeting already T And in endeavors T fourth Sleeping undertake this non-viral patient T the path for tested I’m genetically be the can new that a system place, on manufacturing tremendous delighted to we on individualized, are patients that Beauty unique Beauty and The clinic be cells of Beauty quarter expressed generate adapted processes and to differently, Thus, for to non-viral and a this process can to leveraging cells. patient’s a our be had Rosenberg personalized, successfully scalable the As the cells autologous each report personalized or Dr. system within working manufacturing readily ideally commercial said with the as target in based CARs, plasma remain area to platform go note Sleeping We technologies using of DNA there’s sharing to the buried developed drive the CRADA. on the investigator-initiated neoantigens. provides contrasts these humans. we to patient-specific in different. and approach genetic our is modified manufacturing has not solid TCRs we where TCRs cells a one to to cancer the Sleeping suited neoantigens. have enable practical, the NCI design needs CAR
for within very become likely therapy malignancies for largely possibilities anticipated, area. will hot the Indeed, dwarf which neoantigens targeting the hematologic The therapies solid or recognize of which tumors cancers. market T has offers real to cells a solid that blood combined we are As CAR-T, a area. using ability hot tumors, apply targeting to neoantigens TCR-modified
As such, TCR tumors believe solid other the therein. exciting global of this ways opportunity we’re open therapy wide an and accelerated X. Slide We discussing and we’ve with have parties to TCR opportunities, expand about is program. on we field our with for outreach, filled
or glioblastoma, on our from single Phase the data gene controlled I ASCO year, this in or survival delivering patients with and agent go program, recurrent as updated me At IL-XX address trial platform rGBM. a therapy. for our Let IL-XX we
bevacizumab months and encouraging overall of garners favorably in is compared that prior corticosteroid May study an therapy disease cohort enrollees that of historical of embarked milligrams of the on clinical have GBM enrolling from we’ve a based after to and patients XX.X we shown these of sustained the four controls for in in technology and a mean add controlled patients trial multiple survival patients States survival say, injection which past single been learnings adenovirus, I broaden GBM, overall to the I’ll this established in This feedback platform. further build dosing we as patients that data, steroids population our of XXXX, this platform plus very receiving clinical XX.X the a United To expansion receiving months on not recurrent median time at recurrent reach follow-up in patients this As in low-dose XXX% veledimex. for everyone, refined months, overall with had key the partners. remind to for XX we daily to receiving on a Early are The showed And an efforts sites year, is the dosing potential survival five our this continued Phase median for milligrams not interest. with upon eight and with overall median the why Ad-RTS-hIL-XX past, data or sustained patient initiation. interest will daily veledimex. receiving reason XX based we plan of received weeks of what’s IL-XX their XX to have months. are to with that’s to up And survival the treated
patients Opdivo, First, we’re in with we controlled recurrent immune first a to checkpoint combining And with our past Phase inhibitor, adult IL-XX checkpoint I therapy platform in inhibitors. the patients quarter, dosed IL-XX clinical combination with our GBM. evaluate this in trial the
study, We’re combination our dosing will enrollees additional control patient now up pleased Many to are and recurrent measure single-arm to tried multi-institution doing evaluate to report this in the well, way and establish on and the patient safety regimen, with failed GBM enrolling IL-XX. XX we survival. tolerability this is overall patients many the actively and of have optimal have which
is the potential However, IL-XX put, immune indication further immune powerful immune to regulator that defending themselves such our this and effects. the cytokine. ineffective we reason be as data with learned solid has inhibitor, to such remodeling kickstarting stands PD-X cytokine, successfully harness compromised are this immune the tumors. do clear against this know the the army this a that as tumor. of the company attempted us checkpoints. that or our insufficient not walking This Simply master microenvironment to the forces cascaded anti-PD-X, impact cells so invading combining if rendered cells We out they PD-LX, tumor and inhibitors, T-cells, capable platform are that in the checkpoint many gives of and begin a anticancer The is PD-X system reason with achieve and to checkpoint immune tumor IL-XX and powerful to of will is those work have activity IL-XX, blockading with T important
strong us Our us and sustained partners has potential agent a In establish for become into These see T in wish put ability enables other drive platform. tumors the and data turn clinical clear IL-XX controlled It words, can our as to to do cells cold IL-XX the effect. of drug a IL-XX control that the drug tumor. activity and antitumor a hot. can single indeed plans so to T-cells the tumor with to deep future
both, platform. plan announcing the suggests combination Our more data this controlled of which to that the and we collaboration powerful immune We for types future for forward potential forward of IL-XX, move inhibitors. can or look do one with with we validating potential well bodes – to our checkpoint already in the tumor additional this to cytokine explore
areas. pedal the pushing in We’re all
really technologies remains We platform third-generation positioned well nearing the out board of Sir to formal XX, leadership TCR Slide Director. of the intact. our is two and clinic drive are company, commitment oncology, thanks program I gratitude take core our based each and that strong many his please. to solvable, to want and new the in a partnerships. is a to on collaborations much as little and the Lead Murray trial our just advancing growing with and ZIOPHARM, the We very platform on a world time IL-XX my and our leader offer CDXX hold strengthening Brennan, and my for believe vision targeting producing opportunities, a
Lead years. is over newly discuss board been this company a notably, Fowler, some the for appointed success, steps well-documented Eagle announced Scott? role undertaking, Scott has Director, for a As the of just worked CEO and our leader member of including delighted experienced many who of of well ZIOPHARM current I’m Pharmaceuticals. our and about to distinguished board changes the three history his our a Scott dynamic with week. is valuable as of most the call the Wyche now turn years to Senator has to with And faithfully Tarriff, to
